Tempest Therapeutics, Inc. 8-K

What Happened
Tempest Therapeutics, Inc. (TPST) filed a Form 8‑K on March 30, 2026 (Item 2.02) furnishing a press release that announced the company’s financial results and business highlights for the year ended December 31, 2025. The press release is attached to the filing as Exhibit 99.1 and the report is signed by CEO Matthew Angel.

Key Details

• Filing date: March 30, 2026; reporting period: year ended December 31, 2025.
• The company furnished a press release (Exhibit 99.1) announcing its 2025 financial results and other business highlights.
• The Form 8‑K was furnished under Item 2.02 (Results of Operations and Financial Condition).
• The filing is signed by Matthew Angel, Chief Executive Officer; interactive XBRL data is included (Exhibit 104).

Why It Matters
This filing notifies investors that Tempest publicly released its full-year 2025 results and related business updates. The 8‑K itself furnishes the press release rather than restating numbers in the form text, so investors should read Exhibit 99.1 for details on revenue, net income/loss, cash position, guidance, and any operational or clinical milestones that could affect the stock.